NASDAQ:TCRR

TCR2 Therapeutics News Headlines

$17.27
+0.36 (+2.13 %)
(As of 06/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.58
$17.46
50-Day Range
$16.91
$24.71
52-Week Range
$12.95
$35.86
Volume260,064 shs
Average Volume456,297 shs
Market Capitalization$659.06 million
P/E RatioN/A
Dividend YieldN/A
Beta2.08

TCR2 Therapeutics (NASDAQ TCRR) News Headlines Today

SourceHeadline
TCR2 Therapeutics Inc. (NASDAQ:TCRR) Sees Significant Decrease in Short InterestTCR2 Therapeutics Inc. (NASDAQ:TCRR) Sees Significant Decrease in Short Interest
americanbankingnews.com - June 18 at 8:20 AM
Traders Buy Large Volume of TCR2 Therapeutics Put Options (NASDAQ:TCRR)Traders Buy Large Volume of TCR2 Therapeutics Put Options (NASDAQ:TCRR)
americanbankingnews.com - June 11 at 7:04 AM
TCR2 Therapeutics Inc. (NASDAQ:TCRR) Expected to Post Earnings of -$0.60 Per ShareTCR2 Therapeutics Inc. (NASDAQ:TCRR) Expected to Post Earnings of -$0.60 Per Share
americanbankingnews.com - June 5 at 7:18 PM
TCR2 Therapeutics Inc. (NASDAQ:TCRR) Given Consensus Recommendation of "Buy" by BrokeragesTCR2 Therapeutics Inc. (NASDAQ:TCRR) Given Consensus Recommendation of "Buy" by Brokerages
americanbankingnews.com - June 2 at 1:38 AM
TCR² Therapeutics to Participate in Two Upcoming Conferences in JuneTCR² Therapeutics to Participate in Two Upcoming Conferences in June
finance.yahoo.com - May 26 at 10:12 AM
TCR² Therapeutics to Present at the Truist Securities Life Sciences SummitTCR² Therapeutics to Present at the Truist Securities Life Sciences Summit
finance.yahoo.com - April 29 at 8:32 AM
Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Are In A Position To Invest In GrowthCompanies Like TCR2 Therapeutics (NASDAQ:TCRR) Are In A Position To Invest In Growth
finance.yahoo.com - April 27 at 3:07 PM
TCRR May 2021 20.000 callTCRR May 2021 20.000 call
ca.finance.yahoo.com - April 23 at 12:06 AM
TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual MeetingTCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual Meeting
finance.yahoo.com - April 10 at 1:22 PM
TCR² Therapeutics to Present at the Needham Healthcare ConferenceTCR² Therapeutics to Present at the Needham Healthcare Conference
finance.yahoo.com - April 8 at 7:11 AM
TCRR Jul 2021 35.000 callTCRR Jul 2021 35.000 call
ca.finance.yahoo.com - April 7 at 7:36 AM
TCR² Therapeutics Establishes Commercial-Scale Cell Therapy Manufacturing FacilityTCR² Therapeutics Establishes Commercial-Scale Cell Therapy Manufacturing Facility
finance.yahoo.com - March 29 at 8:22 AM
TCR² Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate UpdateTCR² Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - March 11 at 9:13 AM
TCR² Presentations at American Association of Cancer Research (AACR) Annual Meeting 2021 to Highlight Solid Tumor PipelineTCR² Presentations at American Association of Cancer Research (AACR) Annual Meeting 2021 to Highlight Solid Tumor Pipeline
finance.yahoo.com - March 10 at 7:13 PM
TCR² Therapeutics to Participate in Two Upcoming Conferences in MarchTCR² Therapeutics to Participate in Two Upcoming Conferences in March
finance.yahoo.com - March 3 at 8:26 AM
TCR(2) Therapeutics to Present at SVB Leerink Global Healthcare ConferenceTCR(2) Therapeutics to Present at SVB Leerink Global Healthcare Conference
marketwatch.com - February 17 at 2:16 PM
TCR² Therapeutics to Present at SVB Leerink Global Healthcare ConferenceTCR² Therapeutics to Present at SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 17 at 9:15 AM
TCR² Therapeutics Announces Commercial Cell Therapy Leader Shawn Tomasello Joins its Board of DirectorsTCR² Therapeutics Announces Commercial Cell Therapy Leader Shawn Tomasello Joins its Board of Directors
finance.yahoo.com - February 4 at 9:47 AM
TCR² Therapeutics Announces Pricing of Public Offering of $140.0 Million of Common StockTCR² Therapeutics Announces Pricing of Public Offering of $140.0 Million of Common Stock
finance.yahoo.com - January 19 at 11:44 PM
Kazia Therapeutics Limited (KZIA)Kazia Therapeutics Limited (KZIA)
finance.yahoo.com - January 16 at 8:20 PM
TCR² Therapeutics Announces 2021 Strategic Priorities and MilestonesTCR² Therapeutics Announces 2021 Strategic Priorities and Milestones
finance.yahoo.com - January 8 at 3:19 PM
TCR(2) Therapeutics to Present at J.P. Morgan Healthcare ConferenceTCR(2) Therapeutics to Present at J.P. Morgan Healthcare Conference
marketwatch.com - December 21 at 1:03 PM
TCR² Therapeutics to Present at J.P. Morgan Healthcare ConferenceTCR² Therapeutics to Present at J.P. Morgan Healthcare Conference
finance.yahoo.com - December 21 at 1:03 PM
Thinking about buying stock in Tcr2 Therapeutics, Inovio Pharmaceuticals, BioLineRx, Plug Power, or Arbutus Biopharma?Thinking about buying stock in Tcr2 Therapeutics, Inovio Pharmaceuticals, BioLineRx, Plug Power, or Arbutus Biopharma?
benzinga.com - December 17 at 10:10 PM
Is TCRR A Good Stock To Buy Now?Is TCRR A Good Stock To Buy Now?
finance.yahoo.com - December 14 at 3:25 PM
TCR² Announces RECIST Response in Ovarian Cancer from Ongoing Phase 1/2 Trial of TC-210 in Treatment Refractory Mesothelin-Expressing Solid TumorsTCR² Announces RECIST Response in Ovarian Cancer from Ongoing Phase 1/2 Trial of TC-210 in Treatment Refractory Mesothelin-Expressing Solid Tumors
finance.yahoo.com - December 13 at 2:56 PM
TCR² Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateTCR² Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - November 12 at 7:37 AM
TCR² Therapeutics Announces Partnership with ElevateBio to Expand TC-210 Manufacturing CapacityTCR² Therapeutics Announces Partnership with ElevateBio to Expand TC-210 Manufacturing Capacity
finance.yahoo.com - November 10 at 8:43 AM
What Type Of Shareholders Own The Most Number of TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares?What Type Of Shareholders Own The Most Number of TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares?
finance.yahoo.com - October 27 at 2:13 PM
Piper Sandler: These 2 Healthcare Stocks Could Be the Next M&A TargetPiper Sandler: These 2 Healthcare Stocks Could Be the Next M&A Target
finance.yahoo.com - October 18 at 7:02 AM
TCR2 Therapeutics Inc. (2K7.F)TCR2 Therapeutics Inc. (2K7.F)
in.finance.yahoo.com - October 12 at 9:29 AM
TCR² Therapeutics to Present at Jefferies Cell Therapy Virtual SummitTCR² Therapeutics to Present at Jefferies Cell Therapy Virtual Summit
markets.businessinsider.com - September 29 at 8:35 AM
TCR2 Therapeutics to Participate in Two Upcoming Conferences in SeptemberTCR2 Therapeutics to Participate in Two Upcoming Conferences in September
finance.yahoo.com - September 8 at 12:07 PM
TCR2 Therapeutics EPS misses by $0.03TCR2 Therapeutics EPS misses by $0.03
seekingalpha.com - August 12 at 10:05 AM
TCR² Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateTCR² Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - August 12 at 10:05 AM
Why TCR2 Therapeutics Is Soaring TodayWhy TCR2 Therapeutics Is Soaring Today
finance.yahoo.com - July 27 at 4:54 PM
TCR² Therapeutics Announces Proposed Public Offering of Common StockTCR² Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - July 27 at 4:54 PM
Stock Alert: TCR2 Therapeutics Up 35%Stock Alert: TCR2 Therapeutics Up 35%
markets.businessinsider.com - July 27 at 11:53 AM
TCR2 Therapeutics Releases Positive Solid Tumor DataTCR2 Therapeutics Releases Positive Solid Tumor Data
finance.yahoo.com - July 27 at 11:53 AM
TCR2 Therapeutics TC-210 successful in mid-stage cancer studyTCR2 Therapeutics' TC-210 successful in mid-stage cancer study
seekingalpha.com - July 27 at 6:53 AM
We're Not Very Worried About TCR2 Therapeutics' (NASDAQ:TCRR) Cash Burn RateWe're Not Very Worried About TCR2 Therapeutics' (NASDAQ:TCRR) Cash Burn Rate
finance.yahoo.com - July 27 at 6:53 AM
TCR² Therapeutics to announce interim data from its lead drugs early-stage studyTCR² Therapeutics to announce interim data from its lead drug's early-stage study
seekingalpha.com - July 26 at 10:44 PM
TCR² Therapeutics Announces RECIST Responses with First TC-210 Dose Tested in Advanced Mesothelin-Expressing Solid TumorsTCR² Therapeutics Announces RECIST Responses with First TC-210 Dose Tested in Advanced Mesothelin-Expressing Solid Tumors
finance.yahoo.com - July 26 at 5:43 PM
TCR² Therapeutics to Announce Interim Data from Phase 1/2 Clinical Trial of TC-210 in Mesothelin-Expressing Solid TumorsTCR² Therapeutics to Announce Interim Data from Phase 1/2 Clinical Trial of TC-210 in Mesothelin-Expressing Solid Tumors
finance.yahoo.com - July 24 at 6:30 PM
TCR² Therapeutics to Present at the BMO Prescriptions for Success Healthcare ConferenceTCR² Therapeutics to Present at the BMO Prescriptions for Success Healthcare Conference
finance.yahoo.com - June 17 at 8:23 AM
Hedge Funds Have Never Been This Bullish On TCR2 Therapeutics Inc. (TCRR)Hedge Funds Have Never Been This Bullish On TCR2 Therapeutics Inc. (TCRR)
finance.yahoo.com - June 15 at 12:10 AM
TCR2 Therapeutics Inc (TCRR.OQ)TCR2 Therapeutics Inc (TCRR.OQ)
in.reuters.com - June 8 at 10:56 PM
TCR² Therapeutics Hires Key Business Development and Regulatory Affairs Cell Therapy Experts to Support Strategic ObjectivesTCR² Therapeutics Hires Key Business Development and Regulatory Affairs Cell Therapy Experts to Support Strategic Objectives
finance.yahoo.com - May 27 at 10:07 AM
TCR2 Therapeutics EPS beats by $0.76TCR2 Therapeutics EPS beats by $0.76
seekingalpha.com - May 14 at 10:34 AM
TCR² Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate UpdateTCR² Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - May 14 at 10:34 AM
This page was last updated on 6/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.